• A three-dose, randomized, double-masked, parallel, placebo-controlled ocular tolerance study was undertaken in 12 healthy, normal volunteers with the water-soluble, topical carbonic anhydrase inhibitor MK-927. To our knowledge, this constitutes the first administration of MK-927 to humans. Ten subjects received three drops of 2% MK-927 ophthalmic solution and two subjects received three drops of placebo (vehicle) in one randomly selected eye. Local tolerance of 2% MK-927 was acceptable and supports further clinical trials in patients. Significant intraocular pressure (IOP)-lowering activity was noted when comparing IOP four hours after first dose with that 20 hours predose in the treated eye of subjects receiving MK-927 (mean percent change in IOP, −29.7%; mean change in IOP, −4.6 mm Hg) as opposed to the same comparison for the contralateral, untreated eye (−7.2% and −1.3 mm Hg, respectively). In the two subjects treated with placebo, IOP-lowering activity was not seen in either the placebo-treated eye (−0.4%) or the contralateral, untreated eye (+3.1%).
Lippa EA, von Denffer HA, Hofmann HM, Brunner-Ferber FL. Local Tolerance and Activity of MK-927, a Novel Topical Carbonic Anhydrase Inhibitor. Arch Ophthalmol. 1988;106(12):1694–1696. doi:10.1001/archopht.1988.01060140866029
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: